Advances needed to alleviate burden of retinal disease treatment

We now have our fourth anti-VEGF drug, Beovu from Novartis. Each of the available drugs — Avastin, Lucentis, Eylea and Beovu — typically requires three monthly injections to initiate therapy. After three monthly injections are given, many patients can be converted to less frequent injections, depending on which drug is used, using a treat-and-extend approach. Patients who do not respond to one drug may respond to another. Those of us who comanage these patients with our retina colleagues need to be especially mindful of the postoperative side effects, including uveitis, (Read more...)

Full Story →